Genetics, Risk, and Hope with Ampullary Cancer: Adrienne's Immunotherapy Story скачать в хорошем качестве

Genetics, Risk, and Hope with Ampullary Cancer: Adrienne's Immunotherapy Story

Genetic testing revealed that Adrienne had Lynch Syndrome, which put her at risk of ampullary cancer she later developed. Genetic testing also revealed the tumor biomarkers that got her into the immunotherapy clinical trial that cured her cancer. In 2005, Adrienne learned she had Lynch syndrome, an inherited genetic mutation that significantly increased her risk for several types of cancer. Eight years later, she was diagnosed with metastatic ampullary cancer. She underwent 13 months of chemotherapy, which did not work. When genetic testing of Adrienne’s tumor showed it was MSI high, her oncologist recommended she enroll in a clinical trial for pembrolizumab (Keytruda®). Just over two months later, the cancer was gone. She continued to receive treatment for two years, traveling from her home in New York to Johns Hopkins in Baltimore. Over two years since her last treatment, she remains cancer-free and has returned to her busy life working, spending time with her four daughters, practicing yoga, playing tennis, and traveling with friends and family. https://www.cancerresearch.org/patients This video is part of the 7th Annual Cancer Immunotherapy Month™ in June 2019, hosted by the Cancer Research Institute. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. https://www.cancerresearch.org/join-t... #Immune2Cancer Immunotherapy patient stories are part of Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Sync ID: MB01HIH8WWLJEGC